Each individual's cancer is as unique as their own biology, and every individual's immune system responds differently to cancer.
An immunotherapy approach simply means the stimulation of the immune system to fight disease, which may or may not be specific to an individual's biology.
To achieve maximum, lasting efficacy for patients, IF supports research that integrates the most powerful elements of these different immunotherapies and technologies. This precision immunotherapy approach, pioneered between leaders at University of California - San Diego and the La Jolla Institute for Allergy and Immunology, looks at an individual's biology as the starting point for designing therapies. Treatments are tailored to the unique aspects of an individual's cancer, leveraging their own immune system to most effectively battle disease.
This approach offers virtually endless applications - it is unbound by the restrictions that exist on other kinds of therapies.
As acknowledged by the American Cancer Society in their History of Cancer resource, "cancer treatment has gone through a slow process of development."1 While cancer has been documented by some of the earliest human civilizations, effectively mapping its biology and subsequent treatment has only been made possible in the last few centuries, with radical results. Most readers are likely familiar with the terms chemotherapy and radiation, the results of a surge of new scientific discoveries in the early-to-mid 20th century. These approaches to cancer therapy dominated the standard of care for most of the 20th century, and while they achieve efficacy, the approach does not promise lasting remission, its nonspecific toxicity takes a heavy toll on cancer patients, and offers little hope to patients with metastatic disease, where cancer has spread from its origin site via lymph or blood to other areas of the body. But breakthroughs in re-imagining cancer through the paradigm of immunology have led to completely new possibilities.
"These patients are probably cured" is not something most oncologists get to say about their patients with advanced cancer2. But with the most cutting-edge immunotherapy technologies, researchers and physicians are seeing results that are wholly unprecedented, and previously thought impossible in late stage cancer patients suffering from metastatic disease. At the edge of discovery, transformative results in small sample sets of patients are cause for unprecedented hope, for researchers, patients, and loved ones alike, and inspiring waves of new focused research into this area of study.
While any therapeutic approach that targets and modifies the immune system to fight cancer can be classified as an immunotherapy, several therapies have emerged as some of the most promising classes or groupings. Among them are:
A type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Certain immune checkpoint inhibitors have been approved for the treatment of certain cancers in advanced and less advanced stages - these include drugs like Merck's Keytruda (pembrolizumab), Bristol-Myers Squibb's Opdivo (nivolumab), Roche/Genentech's Tecentriq (atezolizumab), AstraZeneca’s Imfinzi (durvalumab), Pfizer and Merck KGaA’s Bavencio (avelumab), and Sanofi and Regeneron’s cemiplimab (REGN-2810)3. [NCI]
A type of virus that infects and lyses (breaks down) cancer cells but not normal cells. Oncolytic viruses can occur naturally or can be made in the laboratory by changing other viruses. Certain oncolytic viruses are being studied in the treatment of cancer. They may make it easier to kill tumor cells with chemotherapy and radiation therapy. [NCI]
Progress is being made with a form of immunotherapy called adoptive cell transfer or therapy (ACT), which attempts to boost the natural ability of your T cells to fight cancer. In this treatment, T cells are taken from your tumor. Then those that are most active against your cancer are grown in large batches in the lab. The process of growing your T cells in the lab can take 2 to 8 weeks. During this time, you may have treatments such as chemotherapy and radiation therapy to reduce your immune cells. After these treatments, the T cells that were grown in the lab will be given back to you via a needle in your vein. [NCI]
An antibody is a protein that sticks to a specific protein called an antigen. Antibodies circulate throughout the body until they find and attach to the antigen. Once attached, they can recruit other parts of the immune system to destroy the cells containing the antigen. Researchers can design antibodies that specifically target a certain antigen, such as the one found on cancer cells. They can then make many copies of that antibody in the lab. These are known as monoclonal antibodies (mAbs). As researchers have found more antigens linked to cancer, they have been able to make mAbs against more and more cancers. Clinical trials of newer mAbs are now being done on many types of cancer. [NCI]
Cancer vaccines are a type of vaccine that is usually made from a patient’s own tumor cells or from substances taken from tumor cells. A cancer vaccine may help the immune system kill cancer cells. [NCI]
With recent developments in our understanding of the human immune system, immunotherapy is more promising than ever.
IF supports leading scientists as they work, continually deepening this knowledge, and bringing us ever closer to a cure.